Literature DB >> 8191875

Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases.

C Lindberg1, L I Persson, J Björkander, A Oldfors.   

Abstract

Eighteen consecutive patients with inclusion body myositis (IBM) were studied. The mean age of onset of symptoms was 60 years. A typical clinical pattern with insidious onset of muscle weakness in knee extensors and finger flexors combined with dysphagia was observed. Serial measurements of the maximal voluntary muscle strength revealed a mean loss of muscle strength of 1.4% per month. Two of the cases had common variable immunodeficiency, and three cases had reduced levels of the IgG3 subclass. Treatment with prednisone resulted in a temporary improvement of muscle function in three patients. No positive effect of azathioprine or cyclosporine A could be documented. The results show that IBM may be associated with immunodeficiency, and that prednisone treatment may temporarily improve the clinical signs. The results from our studies on the progression of the muscle weakness may provide basis for future studies on treatment of IBM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191875     DOI: 10.1111/j.1600-0404.1994.tb01647.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  17 in total

1.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

Review 2.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 3.  Inclusion body myositis.

Authors:  M J Garlepp; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

4.  Demographic and clinical features of inclusion body myositis in North America.

Authors:  A David Paltiel; Einar Ingvarsson; Donald K K Lee; Richard L Leff; Richard J Nowak; Kurt D Petschke; Seth Richards-Shubik; Ange Zhou; Martin Shubik; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2015-02-17       Impact factor: 3.217

5.  The role of quantitative electromyography in inclusion body myositis.

Authors:  T H Brannagan; A P Hays; D J Lange; W Trojaborg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

6.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Peter A van Doorn; Sjoerd G van Duinen; Baziel G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne de Visser; Jan J G M Verschuuren; Axel R Wintzen
Journal:  J Neurol       Date:  2005-06-17       Impact factor: 4.849

Review 7.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 8.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

9.  Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey.

Authors:  P Serdaroglu Oflazer; F Deymeer; Y Parman
Journal:  Acta Myol       Date:  2011-06

10.  Detecting dysphagia in inclusion body myositis.

Authors:  F M Cox; J J Verschuuren; B M Verbist; E H Niks; A R Wintzen; U A Badrising
Journal:  J Neurol       Date:  2009-07-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.